IM Cannabis Closes Sale of European Operations to CEO-Controlled Entity, Expects C$3M Equity Boost
IMCC sits 29% above its 52-week low of $1.55 on light trading volume (0.1× avg).
Summary
IM Cannabis closed the sale of its European operations to a CEO-controlled entity, expecting a C$3 million improvement in shareholders' equity and reduced liabilities as it refocuses on Israeli medical cannabis.
Key Events · M&A and Partnerships · IMCC
-
European Operations Sale Closed
IM Cannabis completed the sale of IMC Holdings and its European-focused operations to Slil.com Holding Ltd., controlled by CEO Oren Shuster, on September 29, 2026.
-
C$3M Equity Improvement Expected
Management's unaudited pro forma analysis expects the transaction to improve shareholders' equity by approximately C$3 million and reduce consolidated liabilities.
-
Retained Liabilities Capped at C$9.4M
Under the Share Purchase Agreement, aggregate Retained Liabilities of IMC Holdings were not to exceed C$9,400,000, subject to adjustment by mutual agreement.
-
Related Party Transaction
The transaction constituted a related party transaction under MI 61-101 because Slil is beneficially owned by CEO Oren Shuster; the company relied on financial hardship exemptions from formal valuation and minority approval requirements.
Analysis · IMCC · Life Sciences
IM Cannabis completed the sale of its European-focused operations to Slil.com Holding Ltd., a company controlled by CEO Oren Shuster, on September 29, 2026. The transaction is expected to improve shareholders' equity by approximately C$3 million and reduce consolidated liabilities, providing much-needed balance sheet relief for a company that has been raising capital through deeply dilutive convertible notes and facing going concern doubts. The deal was approved by a special committee of independent directors under financial hardship exemptions from Canadian related-party transaction rules, underscoring the company's distressed financial position.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $1.55 to $77.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.